Related Experiment Videos

Prognostic and diagnostic usefulness of serum markers in lung cancer

R A Stahel¹, G Martz

¹Division of Oncology, University Hospital, Zürich, Switzerland.

European Journal of Cancer & Clinical Oncology

|July 1, 1987

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Antibody-drug conjugates in selected solid tumours: a position statement update based on findings from the third workshop held by the ETOP IBCSG Partners Foundation.

ESMO open·2026

A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance - The ETOP 15-19 ABC-lung trial.

Lung cancer (Amsterdam, Netherlands)·2025

Antibody-drug conjugates in lung and breast cancer: current evidence and future directions-a position statement from the ETOP IBCSG Partners Foundation.

Annals of oncology : official journal of the European Society for Medical Oncology·2024

Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis.

ESMO open·2022

A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2021

Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2021

See all related articles